Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Tipo de documento
País/Região como assunto
Ano de publicação
Intervalo de ano de publicação
1.
Dig Liver Dis ; 42(11): 822-5, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20435532

RESUMO

BACKGROUND: Only a small proportion of subjects referring to hospitals for hepatitis C virus (HCV) positivity receives antiviral therapy. AIM: To evaluate the rate of antiviral treatment and the causes for no treatment in HCV-RNA positive subjects seen in hospital settings. PATIENTS AND METHODS: A prospective study enrolling over a 6-month period (February-July 2009) all consecutive anti-HCV positive subjects initially referred (naïve patients) to 12 liver units in Southern Italy for HCV treatment. RESULTS: Out of 608 subjects evaluated, 74 (12.2%) had no detectable HCV-RNA in the serum and thus were excluded. Of the remaining 534 HCV-RNA positive subjects, 357 (66.9%) were not treated for the following reasons: 49.9% were older than 65 years of age (75% of them >70 years), 14.3% had normal liver enzymes, 13.2% had compensated/decompensated cirrhosis, 10.4% refused treatment, 9.8% had ongoing substance or alcohol abuse. Multivariate analysis showed that females (O.R. 2.27; C.I. 95% 1.05-4.90) and subjects with low educational level (O.R. 4.38; C.I. 95% 1.27-15.11) were more likely to decline therapy. CONCLUSIONS: The majority of patients with HCV infection does not receive antiviral treatment. The effectiveness of the current standard therapy for HCV infection is low despite its good efficacy.


Assuntos
Antivirais/uso terapêutico , Hepacivirus , Hepatite C/tratamento farmacológico , Hepatite C/prevenção & controle , Adulto , Idoso , Alanina Transaminase/sangue , Alcoolismo , Antivirais/provisão & distribuição , Escolaridade , Feminino , Hepacivirus/efeitos dos fármacos , Hepacivirus/genética , Hepatite C/epidemiologia , Hepatite C/imunologia , Anticorpos Anti-Hepatite C/sangue , Humanos , Interferon alfa-2 , Interferon-alfa/uso terapêutico , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Polietilenoglicóis/uso terapêutico , Estudos Prospectivos , RNA Viral/sangue , Proteínas Recombinantes , Ribavirina/uso terapêutico , Fatores Sexuais , Resultado do Tratamento , Recusa do Paciente ao Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA